Introduction
============

The relationship between hypercholesterolemia and cardiovascular disease (CVD) has been well established^[@bib1])^. Guidelines for hypercholesterolemia in multiple countries recommend lowering low-density lipoprotein cholesterol (LDL-C) as the primary management target^[@bib2]--[@bib4])^. Although there is no doubt that LDL-C is one of the most important risk factors of CVD^[@bib5])^, even when LDL-C is lowered to recommended levels, cardiovascular events continue to occur. Therefore, we need to manage the novel target as the primary management, or the residual risk of CVD beyond lowering LDL-C^[@bib6])^.

Small dense low-density lipoprotein cholesterol (sdLDL-C) associated with triglyceride-rich lipoprotein (TRL) metabolism, and TRL-cholesterol, which is also known as remnant cholesterol, might be the better factors for the prediction of CVD than total LDL-C^[@bib5],\ [@bib7]--[@bib11])^. In fact, elevated sdLDL-C and remnant cholesterol levels can be found in patients with metabolic abnormalities, such as type 2 diabetes mellitus^[@bib12])^ and metabolic syndrome (MetS)^[@bib13],\ [@bib14])^, which have been found as highly atherogenic conditions with lowgrade inflammation^[@bib15])^.

SdLDL particles were defined as LDL with an average diameter of \< 25.5 nm and had some features related to atherogenic potential, such as increased penetration into the arterial wall by the small sizes, a longer circulation time with low affinity for the LDL receptors, and high susceptibility to oxidation by containing little antioxidative vitamins^[@bib5],\ [@bib16]--[@bib18])^. The Atherosclerosis Risk in Communities study has shown that the cumulative incidence of coronary heart disease (CHD) events was higher among individuals with higher sdLDL-C (hazard ratio (HR): 1.61--1.86) regardless of LDL-C levels, and the Québec Cardiovascular Study has shown that the risk of CHD was increased among men with elevated sdLDL-C (HR:2.1--3.6)^[@bib9],\ [@bib10])^. A roughly-11-year prospective study in Japan also suggested that sdLDL-C could be an independent risk factor for CVD, stroke, and CHD^[@bib5])^. On the other hand, remnant-like particles (RLPs) are highly heterogeneous in size and composition, and RLP cholesterol (RLP-C) is composed of the cholesterol content of very low-density lipoprotein (VLDL) and intermediate-density lipoprotein in the fasted state, and of the two lipoproteins together with chylomicron remnant in the postprandial state^[@bib7])^. There was a causal association between RLP-C and early signs of atherosclerosis with endothelial dysfunction^[@bib19],\ [@bib20])^. Varbo et al. suggested that there was a causal association between elevated nonfasting RLP-C and low-grade inflammation, together with increased risk of CHD^[@bib7])^. Most studies suggested that high RLP-C concentrations, especially in the postprandial state, increase the risk of atherosclerosis and CHD^[@bib8])^.

The basic and subclinical studies support that sdLDLs and RLPs stimulate the innate and adaptive immune cells and induce the inflammatory response playing a primordial role in the pathogenesis of atherosclerosis^[@bib21],\ [@bib22])^. Basic evidence suggests that sdLDL and RLP have some different mechanisms inducing inflammation by activating these immune cells. Smaller LDL particles may have increased proteoglycan binding^[@bib23])^; however, the interaction of sdLDLs, with endothelial cells, macrophages, T cells, and B cells is still under investigation. The high susceptibility to oxidation of sdLDLs contributes to the increased level of modified LDLs. The local inflammation might be further exacerbated by several receptors-dependent inflammatory responses induced by modified LDL^[@bib24])^. On the other hand, RLP, not LDL (1019 \< *d* \< 1063 g/mL), increased the expression levels of adhesion molecules on endothelial cells without binding to glycoproteins that were located at the surface of the endothelium and interleukin-1*β*, which induced vascular inflammation^[@bib20],\ [@bib25],\ [@bib26])^.

Many studies have focused on the mechanism of the inflammation of sdLDL-C or RLP-C per se, with limited data on the association between sdLDL-C and RLP-C in the real-world, population-based setting. Thus, the aim of this study was to investigate the association between sdLDL-C and RLP-C with inflammation.

Methods
=======

Population
----------

The present cross-sectional study was conducted as part of the Jichi Medical School (JMS)-II Cohort Study, a population-based cohort study of 6,436 participants started in 2010 to evaluate the relationship between the risk factors of atherosclerosis and CVD in ordinary Japanese people. Data were obtained from 13 rural districts in Japan between April 2010 and December 2017. In each community, a local government office sent personal invitations for mass CVD screenings to all the subjects by mail. In this study protocol, we selected Japanese people who had undertaken the screening of basic health examination that was conducted in accordance with the medical care system for the elderly and obtained informed consent for this study. The subjects were residents in the Shimotsuke, Kakara, Sue, Omori, Kamiichi, Wara, Takasu, Onabi, Nakatsu, Yame, Miwa, Ueno, and Saji areas of Japan. SdLDL-C and RLP-C were measured in samples from 5,862 participants (2,737 men and 3,125 women). After excluding 557 participants with past history of cancer and/or values of high-sensitivity C-reactive protein (hs-CRP) in excess of 10 mg/L that might represent as an acute-phase response caused by an underlying inflammatory disease, 5,305 participants (2,439 men and 2,866 women) were included in this study.

Measurements
------------

Patients\' height, weight, and waist circumference (WC) were measured using a standardized method, with 0.1 cm, 0.1 kg, and 0.1 cm units of measurement, respectively. Height was measured with stockinged feet. Weight was recorded with the subjects clothed. WC was measured at the navel level while standing, with light exhalation. WC measurements were taken once. Body mass index (BMI) was calculated as weight (kg)/height (m)^2^. Systolic and diastolic blood pressures (BP) were measured with a fully automated sphygmomanometer (Omron HEM-759P; Omron Healthcare Inc., Kyoto, Japan) placed on the right arm of the subjects, who had been resting while seated for five minutes before measurement. BP measurements were repeated twice in the sitting position after a 15-s interval.

Blood samples were taken after overnight fasting and were sent to an external laboratory (SRL, Tokyo, Japan) to measure total cholesterol, triglycerides (TGs), LDL-C, high-density lipoprotein cholesterol (HDL-C), fasting blood glucose, fasting insulin, hs-CRP, RLP-C, and sdLDL-C levels. Total cholesterol was measured by a cholesterol dehydrogenase-ultraviolet method. TG was measured using an enzymatic method. LDL-C and HDL-C were measured via direct methods. Fasting blood glucose was measured by a hexokinase ultraviolet absorption spectrophotometry. Fasting insulin was measured by a chemiluminescent enzyme immunoassay method. Hs-CRP was measured by a nephelometric assay (Inter-assay coefficient of variation (CV): 1.55%, intra-assay CV: 2.21%). RLP-C was measured using an enzymatic method (Until March 2016, Inter-assay CV: 1.65%, intra-assay CV: 2.81%, and since April 2016, Interassay CV: 1.80%, intra-assay CV: 1.96%). The sdLDL-C level is directly and selectively measured using the use of available kits (sdLDL-EX from Denka Seiken, Tokyo, Japan). Serum lipid markers, including sdLDL-C, were measured by the standardized program proposed by the Clinical and Laboratory Standards Institute. The homeostasis model assessment of insulin resistance (HOMA-IR) was defined as the product of fasting insulin (µU/mL) and glucose (mg/dL) divided by 405 ^[@bib27])^. Information about medical history and lifestyle was obtained with a self-reported questionnaire. Questions about past or present illness were asked, and if present, whether the subjects took medicine or not was confirmed. Smoking status was classified as smoking, ex-smoking, or never. All the participants included in the present study provided written informed consent prior to inclusion, and the ethics committees of Jichi Medical University (Tochigi, Japan) and other participating institutions approved the JMS-II Cohort Study protocol (IRB No. G09-39 \[G17-64 revised\]).

Definition
----------

According to Adult Treatment Panel III guidelines^[@bib28])^, MetS was defined as the presence of at least three of five components: abdominal obesity (given as WC \[men \> 102 cm, women \> 88 cm\]), elevated TG (≥ 150 mg/dL), low HDL-C (men \< 40 mg/dL, women \< 50 mg/dL), systolic BP ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg, and high fasting glucose (≥ 110 mg/dL). However, Japanese people are relatively small; therefore, we adopted WC of \> 85 cm for men and \> 90 cm for women as abdominal obesity, as proposed by the Japan Society for the Study of Obesity (JASSO)^[@bib28],\ [@bib29])^. We also defined BMI ≥ 25 as obesity, as proposed by JASSO. Diabetes mellitus was defined as a fasting blood glucose ≥ 126 mg/dL and/or currently being under medication.

Statistical Analysis
--------------------

Data are expressed as mean ± standard deviation, except for sdLDL-C, RLP-C, hs-CRP, TG, and HOMA-IR. The distributions of these markers were highly skewed; these data were expressed as the median and interquartile range and transformed into natural logarithms before statistical analysis. *P*-values for trends across quartiles of sdLDL-C and RLP-C were assessed in an unadjusted model using the Jonckheere-Terpstra test and logistic regression analysis, using quartiles as ordinal variables. Adjusted geometric mean differences in hs-CRP across each quartile were calculated using linear regression analysis. A basic model (model 1) was adjusted for age (continuous), sex, and smoking status, additionally for HOMA-IR, antidyslipidemic medication use, and antihyperglycemic medication use (model 2), and additionally for RLP-C or sdLDL-C (model 3). Odds ratios (OR) and their 95% confidence interval (CI) were estimated with logistic regression models to quantify the association of quartiles of sdLDL-C or RLP-C with obesity, abdominal obesity, and MetS. Pearson\'s linear regression analysis was used to evaluate the relationship between sdLDL-C and RLP-C in the participants. Statistical significance was defined as *p* \< 0.05. Statistical analyses were performed using SPSS version 24 (IBM, Chicago, IL, USA).

Results
=======

Of the 5,305 participants (2,439 men and 2,866 women) in the JMS-II cohort, we classified each sdLDL-C and RLP-C levels into four quartiles, and the baseline characteristics are shown in **[Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}**, respectively. There were significant positive associations between sdLDL-C and RLP-C levels and traditional atherosclerotic risk factors (BMI, WC, BP, serum lipid status, diabetes status, and smoking status). Subjects in the highest sdLDL-C quartile had the highest lipid levels, except for HDL-C. Increasing quartiles of sdLDL-C and RLP-C were significantly associated with increased risks of obesity, abdominal obesity, MetS, and diabetes mellitus. Once adjusted for age, sex, and smoking status, for the second, third, and fourth sdLDL-C quartiles versus the first, the OR (95% CI) for MetS were 1.26 (0.94--1.68), 2.97 (2.30--3.83), and 8.04 (6.31--10.2) (*P* \< 0.001 for trend). For the second, third, and fourth RLP-C quartiles versus the first, the OR (95% CI) for MetS were 1.83 (1.38--2.42), 3.49 (2.69--4.52), and 8.98 (7.00--11.5) (*P* \< 0.001 for trend) (**[Supplementary Table 1](#T6){ref-type="table"}**). Subjects with sdLDL-C and/or RLP-C levels in the highest quartile had the profiles of metabolic abnormalities.

###### Baseline Characteristics and Distribution of Atherosclerotic Risk Factors across Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) Quartiles

                                                          Quartiles of sdLDL-C, mg/dL                                                                     
  ------------------------------------------------------- ----------------------------- -------------------- --------------------- ---------------------- --------------
  Age, years                                              63.0 ± 12.8                   64.5 ± 11.4          64.5 ± 10.5           63.5 ± 10.1            *P* = 0.865
  Male, %                                                 41                            41                   45                    57                     
  BMI, kg/m^2^                                            22.2 ± 3.3                    22.8 ± 3.2           23.3 ± 3.3            24.1 ± 3.3             *P* \< 0.001
  Waist circumference, cm                                 79.9 ± 9.1                    81.8 ± 8.5           83.6 ± 8.8            85.8 ± 8.4             *P* \< 0.001
  Triglycerides, mg/dL                                    68.0 (53.0, 88.0)             81.0 (64.0, 104.0)   103.0 (88.0, 134.0)   153.0 (111.0, 207.8)   *P* \< 0.001
  HDL-C, mg/dL                                            63.9 ± 15.2                   62.6 ± 14.4          58.4 ± 14.8           54.0 ± 12.5            *P* \< 0.001
  RLP-C, mg/dL                                            3.7 (2.8, 5.4)                4.2 (3.1, 6.2)       5.0 (3.8, 7.6)        7.3 (5.1, 12.3)        *P* \< 0.001
  Total cholesterol, mg/dL                                177.9 ± 24.2                  201.2 ± 24.7         211.8 ± 28.1          229.5 ± 30.9           *P* \< 0.001
  LDL-C, mg/dL                                            94.5 ± 20.4                   116.8 ± 21.0         127.4 ± 24.6          139.1 ± 29.9           *P* \< 0.001
  Systolic blood pressure, mmHg                           131.6 ± 20.4                  135.0 ± 20.2         137.0 ± 20.5          139.8 ± 20.6           *P* \< 0.001
  Diastolic blood pressure, mmHg                          77.3 ± 11.3                   79.2 ± 11.0          80.3 ± 11.6           83.0 ± 12.0            *P* \< 0.001
  Fasting glucose, mg/dL                                  97.5 ± 17.4                   98.2 ± 16.2          101.6 ± 20.9          103.4 ± 21.7           *P* \< 0.001
  HOMA-IR                                                 0.84 (0.55, 1.30)             0.98 (0.65, 1.53)    1.14 (0.76, 1.81)     1.39 (0.88, 2.17)      *P* \< 0.001
  Smoking                                                                                                                                                 
      Current, %                                          12                            11                   14                    16                     *P* = 0.001
      EX, %                                               23                            24                   26                    32                     *P* \< 0.001
      Never, %                                            65                            65                   60                    52                     *P* \< 0.001
  Obesity, %[\*](#tf1){ref-type="table-fn"}               17                            20                   26                    34                     *P* \< 0.001
  Metabolic syndrome, %                                     7                             9                  19                    39                     *P* \< 0.001
  Diabetes mellitus, %[\*\*](#tf2){ref-type="table-fn"}   11                              9                  11                    12                     *P* = 0.038
  Antihyperglycemic medication use, %                       8                             6                    8                     7                    *P* = 0.467
  Antidyslipidemic medication use, %                      10                            12                   12                    11                     *P* = 0.828
  Past history^[\$](#tf3){ref-type="table-fn"}^                                                                                                           
      Dyslipidemia, %                                     14                            18                   22                    30                     *P* \< 0.001
      Stroke, %                                             3                             2                    2                     1                    *P* = 0.119
      Myocardial infarction, %                              3                             2                    2                     2                    *P* = 0.031

Data are expressed as mean ± standard deviation (SD), %, and median (25^th^ percentile, 75^th^ percentile). *P*-values for trends across quartiles of sdLDL-C were assessed in an unadjusted model using the Jonckheere--Terpstra test and logistic regression analysis using quartiles as ordinal variables. BMI = body mass index; HDL-C = high-density lipoprotein cholesterol; RLP-C = remnant-like particle cholesterol; LDL-C = low-density lipoprotein cholesterol.

Obesity was considered BMI ≥ 25.

Diabetes mellitus was fasting blood glucose . 126 mg/dL and/or currently under medication.

Data were obtained by questionnaire.

###### Baseline Characteristics and Distribution of Atherosclerotic Risk Factors across Remnant-Like Particle Cholesterol (RLP-C) Quartiles

                                                          Quartiles of RLP-C, mg/dL                                                                     
  ------------------------------------------------------- --------------------------- -------------------- --------------------- ---------------------- --------------
  Age, years                                              64.1 ± 11.6                 64.3 ± 11.3          64.2 ± 10.7           62.8 ± 11.2            *P* = 0.001
  Male, %                                                 47                          42                   42                    53                     
  BMI, kg/m^2^                                            22.2 ± 3.1                  22.9 ± 3.3           23.3 ± 3.4            23.9 ± 3.3             *P* \< 0.001
  Waist circumference, cm                                 80.3 ± 8.6                  82.3 ± 8.9           83.5 ± 9.1            85.0 ± 8.6             *P* \< 0.001
  Triglycerides, mg/dL                                    65.0 (51.0, 82.0)           84.0 (65.0, 106.0)   107.0 (79.0, 138.0)   158.0 (115.0, 220.0)   *P* \< 0.001
  HDL-C, mg/dL                                            63.5 ± 13.9                 62.3 ± 14.9          59.8 ± 14.8           53.1 ± 13.4            *P* \< 0.001
  SdLDL-C, mg/dL                                          25.3 (20.2, 31.7)           31.4 (24.2, 40.8)    36.5 (26.8, 47.2)     42.3 (30.6, 55.7)      *P* \< 0.001
  Total cholesterol, mg/dL                                187.2 ± 27.3                204.1 ± 28.7         212.9 ± 31.7          216.3 ± 35.6           *P* \< 0.001
  LDL-C, mg/dL                                            104.9 ± 24.1                120.0 ± 26.0         127.2 ± 28.7          125.9 ± 32.3           *P* \< 0.001
  Systolic blood pressure, mmHg                           134.1 ± 21.3                135.2 ± 19.5         136.7 ± 21.4          137.4 ± 20.0           *P* \< 0.001
  Diastolic blood pressure, mmHg                          78.7 ± 11.8                 79.3 ± 11.2          80.4 ± 11.5           81.6 ± 12.1            *P* \< 0.001
  Fasting glucose, mg/dL                                  98.4 ± 16.8                 99.0 ± 16.7          100.9 ± 20.5          102.5 ± 22.6           *P* \< 0.001
  HOMA-IR                                                 0.88 (0.58, 1.37)           1.04 (0.65, 1.64)    1.12 (0.73, 1.81)     1.31 (0.83, 2.11)      *P* \< 0.001
  Smoking                                                                                                                                               
      Current, %                                          11                          12                   12                    17                     *P* \< 0.001
      EX, %                                               28                          24                   25                    29                     *P* = 0.340
      Never, %                                            61                          64                   62                    54                     *P* \< 0.001
      Obesity, %[\*](#tf4){ref-type="table-fn"}           16                          21                   27                    33                     *P* \< 0.001
  Metabolic syndrome, %                                     7                         11                   18                    37                     *P* \< 0.001
  Diabetes mellitus, %[\*\*](#tf5){ref-type="table-fn"}     9                         10                   11                    13                     *P* = 0.001
  Antihyperglycemic medication use, %                       6                           7                    7                     8                    *P* = 0.152
  Antidyslipidemic medication use, %                      10                          11                   11                    13                     *P* = 0.035
  Past history^[\$](#tf6){ref-type="table-fn"}^                                                                                                         
      Dyslipidemia, %                                     14                          20                   23                    27                     *P* \< 0.001
      Stroke, %                                             3                           1                    2                     2                    *P* = 0.283
      Myocardial infarction, %                              3                           1                    2                     2                    *P* = 0.404

Data are expressed as mean ± standard deviation (SD), %, and median (25^th^ percentile, 75^th^ percentile). *P*-values for trends across quartiles of RLP-C were assessed in an unadjusted model using the Jonckheere--Terpstra test and logistic regression analysis using quartiles as ordinal variables. BMI = body mass index; HDL-C = high-density lipoprotein cholesterol; SdLDL-C = small dense low-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.

Obesity was considered BMI ≥ 25.

Diabetes mellitus was fasting blood glucose ≥ 126 mg/dL and/or currently under medication.

Data were obtained by questionnaire.

###### Percentages and Adjusted Odds Ratio (95% CI) for Obesity, Abdominal Obesity, and Metabolic Syndrome for Comparison of the Three Highest Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) Quartiles and Remnant-Like Particle Cholesterol (RLP-C) Quartiles with the First Quartile

                                                          Quartiles of sdLDL-C, mg/dL                       Quartiles of RLP-C, mg/dL                                                                                                           
  ------------------------------------------------------- ----------------------------- ------------------- --------------------------- ------------------- ------------------ ------------------- ------------------- ------------------- ---- --------------
  Obesity, %[\*](#tf7){ref-type="table-fn"}               17                            20                  26                          34                  *P* \< 0.001       16                  21                  27                  33   *P* \< 0.001
      model 1                                             1.00 (Reference)              1.29 (1.06--1.58)   1.83 (1.51--2.21)           2.55 (2.12--3.07)   1.00 (Reference)   1.42 (1.17--1.73)   1.94 (1.61--2.34)   2.50 (2.08--3.02)        
  Abdominal Obesity, %[\*\*](#tf8){ref-type="table-fn"}   19                            23                  30                          41                  *P* \< 0.001       20                  27                  30                  37   *P* \< 0.001
      model 1                                             1.00 (Reference)              1.33 (1.10--1.62)   1.89 (1.56--2.28)           2.69 (2.24--3.23)   1.00 (Reference)   1.63 (1.35--1.98)   1.91 (1.59--2.30)   2.40 (1.99--2.88)        
  Metabolic syndrome, %                                   7                             9                   19                          39                  *P* \< 0.001       7                   11                  18                  37   *P* \< 0.001
      model 1                                             1.00 (Reference)              1.26 (0.94--1.68)   2.97 (2.30--3.83)           8.04 (6.31--10.2)   1.00 (Reference)   1.83 (1.38--2.42)   3.49 (2.69--4.52)   8.98 (7.00--11.5)        

Odds ratios are estimated from logistic regression models with adjustments for age, sex, and smoking status.

Obesity was considered BMI ≥ 25.

Abdominal obesity was considered a waist circumference of \> 85 cm for men and \> 90 cm for women.

Of all quartiles of sdLDL-C, the fourth had the highest hs-CRP levels. After adjustments were made for age, sex, and smoking status, sdLDL-C levels were associated with higher hs-CRP. This association also remained significant after additionally adjusting for HOMA-IR, antidyslipidemic medication use, antihyperglycemic medication use, and RLP-C (geometric mean, 95% CI, 0.36 mg/L (0.34--0.38 mg/L), 0.37 mg/L (0.35--0.39 mg/L), 0.40 mg/L (0.37--0.42 mg/L) versus 0.44 mg/L (0.42--0.47 mg/L), *P* \< 0.001 for trend) (**[Table 3](#T3){ref-type="table"}**). Even after adjustment, RLP-C also showed that the fourth had the highest hs-CRP level (geometric mean, 95% CI, 0.35 mg/L (0.33--0.37 mg/L), 0.40 mg/L (0.38--0.43 mg/L), 0.40 mg/L (0.38--0.42 mg/L) versus 0.42 mg/L (0.40--0.45 mg/L), *P* \< 0.001 for trend) (**[Table 4](#T4){ref-type="table"}**).

###### Geometric Mean Values and Adjusted Differences (95% CI) in High-Sensitivity C-Reactive Protein (hs-CRP) across Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) Quartiles

                   Quartiles of sdLDL-C, mg/dL                                                                        
  ---------------- ----------------------------- ---------------------- ---------------------- ---------------------- --------------
  SdLDL-C, mg/dL   18.6                          28.2                   37.7                   56.0                   *P* \< 0.001
                                                                                                                      
  Hs-CRP, mg/L     0.322                         0.355                  0.407                  0.505                  *P* \< 0.001
      model 1      0.331 (0.312--0.351)          0.359 (0.300--0.381)   0.404 (0.381--0.428)   0.490 (0.462--0.519)   *P* \< 0.001
      model 2      0.349 (0.329--0.371)          0.365 (0.344--0.387)   0.397 (0.374--0.421)   0.463 (0.436--0.492)   *P* \< 0.001
      model 3      0.361 (0.340--0.384)          0.371 (0.350--0.394)   0.395 (0.372--0.418)   0.444 (0.417--0.472)   *P* \< 0.001

Data are expressed as geometric mean. Data (95% CI) in tables are estimated from linear regression models with adjustments for age, sex, and smoking status (model 1), as well as additionally for HOMA-IR (log-transformed), antidyslipidemic medication use, and antihyperglycemic medication use (model 2), and additionally for remnant-like particle cholesterol (RLP-C) (log-transformed) (model 3).

###### Geometric Mean Values and Adjusted Differences (95% CI) in High-Sensitivity C-Reactive Protein (hs-CRP) across Remnant-Like Particle Cholesterol (RLP-C) Quartiles

                 Quartiles of RLP-C, mg/dL                                                                        
  -------------- --------------------------- ---------------------- ---------------------- ---------------------- --------------
  RLP-C, mg/dL   2.6                         4.1                    6.0                    13.8                   *P* \< 0.001
                                                                                                                  
  Hs-CRP, mg/L   0.315                       0.392                  0.406                  0.470                  *P* \< 0.001
      model 1    0.314 (0.296--0.333)        0.397 (0.373--0.421)   0.409 (0.386--0.434)   0.463 (0.436--0.491)   *P* \< 0.001
      model 2    0.330 (0.311--0.350)        0.401 (0.378--0.425)   0.405 (0.383--0.429)   0.440 (0.414--0.467)   *P* \< 0.001
      model 3    0.345 (0.325--0.367)        0.404 (0.381--0.428)   0.399 (0.376--0.422)   0.423 (0.398--0.450)   *P* \< 0.001

Data are expressed as geometric mean. Data (95% CI) in tables are estimated from linear regression models with adjustments for age, sex, and smoking status (model 1), as well as additionally for HOMA-IR (log-transformed), antidyslipidemic medication use, and antihyperglycemic medication use (model 2), and additionally for small dense low-density lipoprotein cholesterol (sdLDL-C) (log-transformed) (model 3).

After stratifying the participants into four sdLDL-C × four RLP-C categories and adjusting for age, sex, and smoking status, the group in the fourth sdLDL-C quartile and the fourth RLP-C quartile had the highest hs-CRP levels (Geometric mean, 95% CI, 0.52 mg/L, 0.48--0.57 mg/L) (**[Fig. 1](#F1){ref-type="fig"}**). As shown in **[Table 5](#T5){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}**, sdLDL-C levels were apparently not associated with hs-CRP levels in subjects with the lowest RLP-C group. The result by analysis, including all subjects with a history of cancer and/or inflammatory disease, appeared similar (data not shown). The sub-analysis showed that in the young- to middle-age group (under 65 years) with the lowest RLP-C, the group with the highest sdLDL-C had the highest values of hs-CRP. Conversely, in the elderly group (65 years and over), the group with low sdLDL-C had the highest values of hs-CRP (**[Supplementary Table 2](#T7){ref-type="table"} and [Supplementary Fig. 1](#F2){ref-type="fig"}**). SdLDL-C levels were positively associated with RLP-C (Pearson\'s *r* = 0.443, *P* \< 0.001), and the interaction effect of sdLDL-C and RLP-C on low-grade inflammation was not observed (*P* = 0.754).

![Geometric Mean Values of High-Sensitivity C-Reactive Protein (hs-CRP) After Stratifying the Participants into Four Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) × Four Remnant-Like Particle Cholesterol (RLP-C) Categories and Adjusting for Age, Sex, and Smoking Status](jat-27-319-g001){#F1}

###### Geometric Mean Values and Adjusted Differences (95% CI) of High-Sensitivity C-Reactive Protein (hs-CRP) by Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) and Remnant-Like Particle Cholesterol (RLP-C) Quartiles

                     SdLDL-C, mg/dL                                     
  ------------------ ---------------- ---------------- ---------------- ----------------
  Q4                                                                    
      subjects       605              319              223              149
      Hs-CRP, mg/L   0.521            0.481            0.375            0.364
      (95%CI)        (0.478--0.569)   (0.427--0.542)   (0.324--0.432)   (0.305--0.433)
                                                                        
  Q3                                                                    
      subjects       441              396              276              261
      Hs-CRP, mg/L   0.511            0.392            0.381            0.321
      (95%CI)        (0.462--0.567)   (0.352--0.437)   (0.335--0.434)   (0.281--0.366)
                                                                        
  Q2                                                                    
      Subjects       218              380              381              323
      Hs-CRP, mg/L   0.442            0.419            0.363            0.381
      (95%CI)        (0.382--0.510)   (0.375--0.467)   (0.326--0.406)   (0.339--0.430)
                                                                        
  Q1                                                                    
      Subjects       63               242              435              589
      Hs-CRP, mg/L   0.282            0.318            0.334            0.302
      (95%CI)        (0.215--0.369)   (0.277--0.365)   (0.301--0.370)   (0.277--0.330)

Data are expressed as geometric mean. Data (95% CI) in tables are estimated from linear regression models with adjustments for age, sex, and smoking status.

###### Geometric Mean Values and Adjusted Differences (95% CI) of High-Sensitivity C-Reactive Protein (hs-CRP) by Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) Quartiles in Subjects with The Lowest Remnant-Like Particle Cholesterol (RLP-C) by Age Group

                 SdLDL-C, mg/dL                                     
  -------------- ---------------- ---------------- ---------------- ----------------
  65 years ≦                                                        
  subjects       30               129              241              315
  Hs-CRP, mg/L   0.325            0.360            0.426            0.416
  (95%CI)        (0.221--0.476)   (0.289--0.448)   (0.362--0.502)   (0.362--0.477)
                                                                    
  \< 65 years                                                       
  subjects       44               134              242              347
  Hs-CRP, mg/L   0.335            0.325            0.303            0.263
  (95%CI)        (0.215--0.522)   (0.262--0.403)   (0.259--0.354)   (0.229--0.302)

Data are expressed as geometric mean. Data (95% CI) in tables are estimated from linear regression models with adjustments for age, sex, and smoking status.

![Geometric Mean Values of High-Sensitivity C-Reactive Protein (hs-CRP) by Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) Quartiles in Subjects with The Lowest Remnant-Like Particle Cholesterol by Age Group and Adjusting for Age, Sex, and Smoking Status](jat-27-319-g002){#F2}

Discussion
==========

Our study of 5,305 JMS-II participants found that sdLDL-C and RLP-C were significantly and positively associated with not only metabolic abnormalities but also low-grade inflammation marked by hs-CRP. To the best of our knowledge, the present study is the first to demonstrate the association between sdLDL-C levels and low-grade inflammation, independently of RLP-C, in a real-world, population-based setting. SdLDL-C and RLP-C have different associations with low-grade inflammation, and the interaction effect of sdLDL-C and RLP-C on lowgrade inflammation was not observed. Our results partially supported the hypothesis that sdLDL-C and RLP-C mediate the association between metabolic abnormalities and low-grade inflammation^[@bib5],\ [@bib7]--[@bib9],\ [@bib30])^. However, both sdLDLs and remnants are regulated through multiple mechanisms, which are composed of excess adiposity, free fatty acids (FFAs), apolipoproteins such as ApoC-II, ApoC-III, and ApoE, and the other factors, including inhibition of lipoprotein lipase activity, delayed catabolism of TRLs, action of cholesterol ester transfer protein for lipoproteins, and promotion of larger VLDL secretion by increased triglyceride synthesis^[@bib9],\ [@bib11],\ [@bib13],\ [@bib31],\ [@bib32])^. Excess adiposity and FFAs were also involved in the pathogenesis of insulin resistance and MetS. These regulations and relationships are very complex, and we require additional longitude cohorts to evaluate a causal relationship between MetS and sdLDL-C or RLP-C.

In the past era, atherosclerosis was considered to be a cholesterol storage disease characterized by the collection of cholesterol and thrombotic debris in the artery wall. Multiple studies showed that inflammation played an important role in the pathogenesis of atherosclerosis. Inflammation is involved in the initiation and progression of the plaques, and could regulate the plaque biology that triggers the thrombotic complications of atherosclerosis^[@bib33]--[@bib35])^. The lipoprotein components modified by several enzymes lead to the focal activation of endothelium and formation of several damage-associated molecular patterns, which can activate innate immune cells such as macrophage cells^[@bib21])^. In addition to the innate immunity, multiple types of evidence support that a role for the adaptive immunity in plaque progression with inflammation. The self- and non-self-antigens can contribute to vascular inflammation by triggering the activation of T and B cells locally^[@bib22])^. Candidate antigens for stimulation of this adaptive immune response include modified or native lipoproteins and apolipoprotein B-100. Therefore, it is likely that both sdLDLs and RLPs cooperate with the innate and adaptive immune cells and collectively induce the inflammatory response. Furthermore, several studies suggest that sdLDL and RLP had some different mechanisms activating the immune cells^[@bib20],\ [@bib23]--[@bib25],\ [@bib30])^. The finding of the present study that sdLDL-C and RLP-C had different associations with low-grade inflammation in a real-world, population-based setting, might reflect, in part, these different mechanisms of activating the immune cells.

Indeed, hs-CRP, which reflected systemic inflammation, was associated with future CHD events and the risk of death in a general population^[@bib36],\ [@bib37])^. The Hisayama study, which is a population-based prospective cohort study, suggested that hs-CRP levels were related linearly to future CHD events across a wide range of values in a general Japanese population^[@bib36])^. The study also showed that the association between hs-CRP levels and CHD was strong and continuous from very low hs-CRP levels of less than about 0.2 mg/L, and a slightly elevated hs-CRP level of more than 1.0 mg/L, which was much lower than that for Western populations, was likely to be clearly associated with high risk of future cardiovascular events in Japanese. In our study, the differences in hs-CRP levels between the groups with the lowest and the highest sdLDL-C, RLP-C, and combined sdLDL-C and RLP-C were approximately 0.08, 0.08, and 0.22 mg/L (**[Table 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, and [Fig. 1](#F1){ref-type="fig"}**). Although our assessment for the risk of CVD was limited, according to these data and a linear function made by the data of the Hisayama study, the risk of CHD might be about 1.6-fold greater in the group with the highest combined sdLDL-C and RLP-C, compared with the group with the lowest combined sdLDL-C and RLP-C.

As shown in **[Supplementary Table 2](#T7){ref-type="table"}**, we found that the group with the lower sdLDL-C had the highest hs-CRP levels in elderly participants with the lowest RLP-C. For impaired lipid metabolism in patients with chronic liver diseases or some cancers, which cause tissue inflammation and increase hs-CRP levels, hypocholesterolemia states are frequently observed^[@bib38])^. Therefore, chronic diseases being undiagnosed might be considered the causal factor. Further studies are needed to determine the association.

This study has several limitations. First, the cross-sectional design of our study cannot support the causal relationships between sdLDL-C and RLP-C and metabolic abnormalities or low-grade inflammation. Second, data regarding type and dose of medications for diabetes mellitus or dyslipidemia were not available. However, after exclusion of subjects taking medication for these diseases, the results remained identical (data not shown). Third, although the association between atherosclerotic risk markers, including hs-CRP, and sdLDL-C and/or RLP-C may explain a possible link between sdLDL-C and/or RLP-C and the risk of CVD and mortality, the true relationship is unclear. This study did not show the associations of sdLDL-C and RLP-C with prognostic outcomes. Further studies are necessary to clarify these relationships.

Conclusions
===========

In conclusion, sdLDL-C was associated with low-grade inflammation marked by elevated hs-CRP levels. SdLDL-C and RLP-C have different associations with inflammation, and there were combined effects of sdLDL-C and RLP-C on low-grade inflammation in a real-world, population setting. These results indicate that they might increase the risk for CVD through multiple different mechanisms and support sdLDL-C as the potential novel factor of CVD in relation to inflammation, independently of RLP-C.
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